Publications by authors named "Anja Barac Nekic"
Background: Mitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events.
Methods: A retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane.
Background: While numerous studies have explored treatment outcomes for the overall ACC patient cohort, data on the subpopulation of patients with recurrent disease are limited. Therefore, the aim of this study was to assess treatment outcomes in patients with recurrent ACC.
Methods: In this retrospective study, we included 18 patients median age 49 years (42-62); 67% female) diagnosed with recurrent ENSAT stage I-III ACC who underwent either R0 ( = 16) or Rx ( = 2) surgical resection of the tumor.
Are comorbidities of patients with adrenal incidentaloma tied to sex?
Front Endocrinol (Lausanne)
May 2024
Background: A recent cross-sectional study showed that both comorbidities and mortality in patients with adrenal incidentaloma (AI) are tied to sex. However, few longitudinal studies evaluated the development of arterial hypertension, hyperglycemia, dyslipidemia and bone impairment in patients with AI. The aim of this study is to analyze the impact of sex in the development of these comorbidities during long-term follow-up.
View Article and Find Full Text PDFArticle Synopsis
- Researchers looked at how cortisol, a hormone, affects the death rates in people with adrenal incidentalomas, which are growths on the adrenal glands found by accident.
- They studied over 3,600 patients from different countries to see if high cortisol levels linked to more health problems and heart issues.
- The study found that out of the patients, about 10% died over an average of 7 years, and they analyzed other health conditions that might be related to these adrenal growths.
Complete surgical removal of adrenocortical carcinoma (ACC) represents the only chance of long-term cure. In this study, we compared the long-term outcomes of ACC patients depending on whether they had adrenal surgery performed in a high-volume (HVC) or in a low-volume (LVC) center. This retrospective study included 49 patients from the Croatian ACC Registry with the European Network for the Study of Adrenal Tumors (ENSAT) stage I-III ACC, of which 35 underwent surgery in a HVC whereas 14 of them were operated in one of the LVCs.
View Article and Find Full Text PDF